TY - JOUR
T1 - Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort
AU - van Stigt, Arthur H.
AU - Oude Rengerink, Katrien
AU - Bloemenkamp, Kitty W.M.
AU - de Waal, Wouter
AU - Prevaes, Sabine M.P.J.
AU - Le, Thuy My
AU - van Wijk, Femke
AU - Nederend, Maaike
AU - Hellinga, Anneke H.
AU - Lammers, Christianne S.
AU - den Hartog, Gerco
AU - van Herwijnen, Martijn J.C.
AU - Garssen, Johan
AU - Knippels, Léon M.J.
AU - Verhagen, Lilly M.
AU - de Theije, Caroline G.M.
AU - Leusen, Jeanette H.W.
AU - Lopez-Rincon, Alejandro
AU - van’t Land, Belinda
AU - Bont, Louis
AU - PRIMA Initiative Group
AU - Knulst, André C.
AU - van der Ent, C. Kors
AU - van Baarle, Debbie
AU - Wauben, Marca H.M.
AU - Rots, Nynke Y.
AU - Sanders, Elisabeth A.M.
AU - Benders, Manon J.N.L.
AU - Meulenbroek, Laura A.M.P.
AU - Stahl, Bernd
AU - Kraneveld, Aletta D.
AU - Buiteman, Brigitte J.M.
AU - Voogt, Tanja
AU - van der Meij, Barbara
AU - Lerkvaleekul, Butsabong
AU - Voogd, Eline
AU - Lalmahomed, Tariq A.
AU - Brus, Iris M.
AU - van Meerwijk, Daphne M.M.
AU - Jepma, Sophie I.E.
N1 - Funding Information:
The study was funded by grants from the Dutch Ministry of Health, Welfare and Sport, the Wilhelmina Children’s Hospital and Nutricia B.V. None of the authors have a competing financial interest in relation to the presented work; JG, LK and BL are (partly) employed by Danone Nutricia Research.
Funding Information:
This research was supported by Regio Deal Foodvalley (grant nr 162135), the WKZ research fund-Nutricia call 2020 “Breast milk T cells: frontline protection for infants and mothers?” and from Danone Nutricia Research BV as part of a UMC Utrecht-Danone Nutricia Research BV collaboration grant “Early Life Nutrition and Immune Development” (Ministerie van Volksgezondheid, Welzijn en Sport, Universitair Medisch Centrum Utrecht, Danone Nutricia Research BV). The funders had no role in the study design, in the collection, analysis and interpretation of data. The funders had no role in the final decisions on the interpretation and dissemination of the results.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Many studies support the protective effect of breastfeeding on respiratory tract infections. Although infant formulas have been developed to provide adequate nutritional solutions, many components in human milk contributing to the protection of newborns and aiding immune development still need to be identified. In this paper we present the methodology of the “Protecting against Respiratory tract lnfections through human Milk Analysis” (PRIMA) cohort, which is an observational, prospective and multi-centre birth cohort aiming to identify novel functions of components in human milk that are protective against respiratory tract infections and allergic diseases early in life. Methods: For the PRIMA human milk cohort we aim to recruit 1000 mother–child pairs in the first month postpartum. At one week, one, three, and six months after birth, fresh human milk samples will be collected and processed. In order to identify protective components, the level of pathogen specific antibodies, T cell composition, Human milk oligosaccharides, as well as extracellular vesicles (EVs) will be analysed, in the milk samples in relation to clinical data which are collected using two-weekly parental questionnaires. The primary outcome of this study is the number of parent-reported medically attended respiratory infections. Secondary outcomes that will be measured are physician diagnosed (respiratory) infections and allergies during the first year of life. Discussion: The PRIMA human milk cohort will be a large prospective healthy birth cohort in which we will use an integrated, multidisciplinary approach to identify the longitudinal effect human milk components that play a role in preventing (respiratory) infections and allergies during the first year of life. Ultimately, we believe that this study will provide novel insights into immunomodulatory components in human milk. This may allow for optimizing formula feeding for all non-breastfed infants.
AB - Background: Many studies support the protective effect of breastfeeding on respiratory tract infections. Although infant formulas have been developed to provide adequate nutritional solutions, many components in human milk contributing to the protection of newborns and aiding immune development still need to be identified. In this paper we present the methodology of the “Protecting against Respiratory tract lnfections through human Milk Analysis” (PRIMA) cohort, which is an observational, prospective and multi-centre birth cohort aiming to identify novel functions of components in human milk that are protective against respiratory tract infections and allergic diseases early in life. Methods: For the PRIMA human milk cohort we aim to recruit 1000 mother–child pairs in the first month postpartum. At one week, one, three, and six months after birth, fresh human milk samples will be collected and processed. In order to identify protective components, the level of pathogen specific antibodies, T cell composition, Human milk oligosaccharides, as well as extracellular vesicles (EVs) will be analysed, in the milk samples in relation to clinical data which are collected using two-weekly parental questionnaires. The primary outcome of this study is the number of parent-reported medically attended respiratory infections. Secondary outcomes that will be measured are physician diagnosed (respiratory) infections and allergies during the first year of life. Discussion: The PRIMA human milk cohort will be a large prospective healthy birth cohort in which we will use an integrated, multidisciplinary approach to identify the longitudinal effect human milk components that play a role in preventing (respiratory) infections and allergies during the first year of life. Ultimately, we believe that this study will provide novel insights into immunomodulatory components in human milk. This may allow for optimizing formula feeding for all non-breastfed infants.
UR - https://www.scopus.com/pages/publications/85124604169
U2 - 10.1186/s12879-022-07107-w
DO - 10.1186/s12879-022-07107-w
M3 - Article
C2 - 35164699
AN - SCOPUS:85124604169
SN - 1471-2334
VL - 22
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 152
ER -
SDG 3 Good Health and Well-being